Share this article
Share this article
SAN DIEGO, March 1, 2021 /PRNewswire/ -- Agena Bioscience®, a global provider of low-cost, high-throughput molecular testing solutions, today announced the launch of the MassARRAY® SARS-CoV-2 Variant Panel (RUO) for the detection of key SARS-CoV-2 virus strains, including the UK (B.1.1.7), South Africa (B.1.351), Brazil (P.1) and Denmark (Cluster 5) variants.
The MassARRAY® technology is a benchtop system that provides timely and accurate analysis of up to 1000s of samples in a single day. For SARS-CoV-2, influenza A, and influenza B targets, the platform enables accurate detection with comprehensive coverage.
Clinical laboratories can process thousands of samples each day on a single MassARRAY instrument. This makes the new panel one of the highest throughput SARS-CoV-2 variant surveillance tests on the market, and at $25 per sample, a compelling alternative to more costly and complex sequencing technologies.